about
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerThe First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.Detection of circulating tumor DNA in early- and late-stage human malignanciesTumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistanceTumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.Integrating liquid biopsies into the management of cancer.MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.Minimal residual disease in breast cancer: in blood veritas.Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsWhole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
P50
Q24563539-6C655ACC-03A8-437E-A9A4-CF8419840D51Q24604601-5294405B-76C1-4598-BB65-415852F4963EQ27853340-F0E62A28-0DA8-456C-A6C0-BADB5E5EDEADQ27853380-E253DDDA-1EBA-4CDF-964D-B0233EDDA6F4Q27853393-945FD4D5-F07D-44C6-AB4B-8DE68CA0B324Q29615778-1458E8CB-516B-4868-B46B-72C251654136Q36989342-3C258D5B-BC5D-45AE-8844-2EF54F723BF0Q38249332-783FA808-8CAB-4AA6-AEEB-2E9EE663B37DQ38275060-E7DF4135-5829-4D60-824F-E31D663684F4Q38376337-C7C7C378-ECE6-4291-98A4-BB128E77F8CEQ38377594-20284394-D50B-48E6-BE72-A661DC699803Q38699032-BB45E46C-3FA0-4FB7-85BA-32DA27D8E5ABQ38706872-ED3BEDE8-62A3-4B82-99B7-D2931A1D3075Q38764035-FF448E60-4AA3-4A58-B638-5F8A0A840409Q38776411-681AA8C1-DBD4-44CF-B62F-A6749347F1F7Q38821392-4F74996D-37B9-4EC0-B457-9B7249A6A4FDQ38916276-5FE23C73-B85D-4A55-8BD0-528DCD006B50Q39120801-94989004-2F15-48CA-96A8-55C34AAFB6B3Q39157824-A16EDD60-C7CA-4CE0-908F-6C8E1D3D7068Q40026210-63709902-29D8-4534-BBFC-C1B60D37F0A1Q40179385-7525C529-2E31-42A2-9D46-EDA4AD089DEBQ40291585-1C30B106-0A12-420D-9515-56B13AD2AD5BQ42183079-60E0D4F8-D810-41EA-9258-4BCADF5AEA6EQ42689844-B506A9A4-5D72-42B7-AE3D-EDC21DF376ACQ43142381-2E04D612-C0BB-46B0-B3EC-812989061DD4Q47382737-50B41176-5C84-4F93-AB59-0CB5DA7529B3Q48562940-48DE7057-8614-46F0-8AD9-FCF308E6D192Q49551908-0E40CEA3-2D4D-4144-A49A-C910B40BCFBDQ51752412-581766DC-E16A-48E7-814F-410AA2E1EC49Q57280710-44D41B04-A1A5-4340-9F2C-AF87EC96B96DQ57280718-F6D51676-E42D-45D1-8B2A-353AE2BE062DQ90156140-3002B1FC-E67E-4C9B-9B40-76F5031B4673
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giulia Siravegna
@ast
Giulia Siravegna
@en
Giulia Siravegna
@es
Giulia Siravegna
@nl
type
label
Giulia Siravegna
@ast
Giulia Siravegna
@en
Giulia Siravegna
@es
Giulia Siravegna
@nl
prefLabel
Giulia Siravegna
@ast
Giulia Siravegna
@en
Giulia Siravegna
@es
Giulia Siravegna
@nl
P106
P1153
55256240200
P21
P31
P496
0000-0002-7132-6484